Compugen

-$0.14 (-7.49%) Today

$0.00 (0.00%) As of 9:59 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Compugen and other ETFs, options, and stocks.

About CGEN

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases.

CEO

Anat Cohen-Dayag

Employees

Headquarters

Holon, Tel Aviv

Founded

1993

CGEN Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

1.10M

High today

$1.82

Low today

$1.69

Open price

$1.80

Volume

946.81K

52 Week high

$9.20

52 Week low

$1.66

CGEN News

Simply Wall StMay 19

Individual investors who hold 49% of Compugen Ltd. gained 12%, institutions profited as well - Simply Wall St

If you want to know who really controls Compugen Ltd. ( ), then you'll have to look at the makeup of its share registry. And the group that holds the biggest pi

Analyst ratings

Buy

100%

Hold

Sell

CGEN Earnings

-$0.13

-$0.11

-$0.09

-$0.07

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Estimated

-$0.13 per share

Actual

-$0.11 per share

Why Robinhood?

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. View more

Individual investors who hold 49% of Compugen Ltd. gained 12%, institutions profited as well - Simply Wall St

100%

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases.